BiotechTube
Y-mAbs Therapeutics

Y-mAbs Therapeutics

New York, United States· Est.
ymabs.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $280M

Overview

Y-mAbs Therapeutics, founded in 2015 and headquartered in New York, is a commercial-stage biotech company specializing in antibody-based oncology treatments. Its lead asset, DANYELZA, is an FDA-approved therapy for relapsed/refractory high-risk neuroblastoma, representing a significant advancement for a rare pediatric cancer. The company is now part of SERB Pharmaceuticals, which provides strategic and financial backing for its pipeline development. Y-mAbs continues to leverage its expertise in radioimmunotherapy and antibody engineering to address unmet needs in solid tumors.

OncologyPediatric Oncology

Technology Platform

Radioimmunotherapy and bispecific antibody platforms for targeted cancer treatment, focusing on antigens like GD2 and B7-H3.

Funding History

4
Total raised:$280M
PIPE$125M
IPO$85M
Series B$50M
Series A$20M

Opportunities

Expanding DANYELZA into earlier lines of neuroblastoma therapy and exploring combination regimens represents a near-term growth opportunity.
The B7-H3 target (for omburtamab) is expressed on a wide range of solid tumors, offering a pathway to address larger adult oncology markets if clinical development is successful.

Risk Factors

Key risks include the potential failure of the confirmatory trial for DANYELZA's accelerated approval, the uncertain regulatory path for omburtamab following a previous CRL, and the challenges of commercializing a high-cost therapy in a small, competitive rare disease market.

Competitive Landscape

In neuroblastoma, DANYELZA competes with other GD2-targeting antibodies, notably dinutuximab (Unituxin). The broader radioimmunotherapy and bispecific antibody space is highly competitive, with numerous large pharmaceutical and biotechnology companies developing advanced oncology platforms targeting various antigens.

More companies in Antibody-Drug Conjugates →More companies in United States →